Goldman Commits Debt to Support Valeant, Bausch + Lomb Deal
Valeant Pharmaceuticals and Bausch + Lomb announced an agreement under which Valeant will acquire the eye health company for $8.7 billion. Goldman Sachs USA is said to have committed debt financing to support the transaction.
May 28, 2013
Goldman Sachs | Lomb Deal Valeant | Lomb Holdings | Pharmaceuticals International
ABFJ News